Citigroup and UBS Maintain Neutral on Moderna, Inc. (MRNA) Feb 2026

Citigroup and UBS on February 16, 2026 maintained Neutral ratings on Moderna, Inc. (MRNA) while raising price targets to $41 and $36 respectively, signaling measured confidence without a full Buy call. The MRNA analyst rating shows price target lifts but no change in conviction. Investors get clearer earnings and pipeline signals, but firms stop short of endorsing a rally. We review each firm’s note, the price targets, market context, and what the MRNA analyst rating means for shareholders and traders.

MRNA analyst rating overview

Both Citigroup and UBS left fundamentals-based ratings unchanged on February 16, 2026. Citigroup maintained Neutral and raised its price target to $41 from $28. UBS maintained Neutral and nudged its price target to $36 from $34. These moves reflect revised forecasts, not a directional buy or sell recommendation.

Details of Citigroup action and note

Citigroup on February 16, 2026 kept a Neutral stance while increasing its price target to $41 from $28, highlighting improved model assumptions or revenue outlook. Read Citi’s change reported by The Fly for the full note source. This larger jump in target suggests Citi now expects stronger near-term cash flow or label expansions.

Details of UBS action and note

UBS on February 16, 2026 maintained Neutral while lifting the price target modestly to $36 from $34, signaling incremental confidence in Moderna’s near-term operating metrics. See UBS’s update as summarized by The Fly source. UBS’s move is more conservative than Citi’s, reflecting cautious revenue or margin expectations.

Price targets, market context, and performance link

The two price targets now sit at $41 and $36 against a market cap of $16,500,681,448. If MRNA trades near the low $40s, Citi’s target is close to current levels while UBS’s target sits below. Investors should compare targets to the stock price to assess upside and downside implied by each MRNA analyst rating.

What the MRNA analyst rating changes mean for investors

Maintained Neutral with higher targets means analysts see better outcomes but not enough to flip to Buy. For investors, this implies moderated upside, higher conviction in specific revenue streams, and continued model uncertainty. Short-term traders may react to target revisions. Long-term holders should weigh pipeline and cash flow versus these revised targets.

Historical analyst coverage and Meyka AI grade

Analyst coverage of Moderna has varied across Buy, Hold, and Reduce over recent years as product cycles changed. Meyka AI rates MRNA with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. See our Meyka MRNA page for more context Meyka MRNA page.

Final Thoughts

The February 16, 2026 MRNA analyst rating updates from Citigroup and UBS show cautious optimism. Both firms maintained Neutral while lifting price targets to $41 and $36 respectively, indicating improved forecasts without stronger conviction. For investors, the revisions narrow uncertainty but do not signal a clear buy recommendation. Traders should monitor upcoming earnings, label news, and pipeline readouts that could change analyst stances. Compare the price targets to the current share price to calculate implied upside and downside. Remember, Meyka AI rates MRNA with a grade of B based on S&P 500 benchmarking, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and do not constitute financial advice. Use this MRNA analyst rating update as one input among company filings, macro factors, and personal risk tolerance when sizing positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.